FDA Requires New Eye-Risk Warnings on GLP-1 Drugs
The FDA found very few probable cases, but is requiring labels to flag a rare condition that can cause sudden, painless vision loss.
By shahzad
7 min read2 readers
In this story
Key takeaways
On November 9, 2026, the FDA said makers of all GLP-1 receptor agonist medicines must add label warnings about a potential increased risk of a rare eye condition called NAION.
In 126 randomized trials involving 134,253 people, the FDA identified 15 probable NAION cases. The reported rate was 6.4 per 100,000 person-years among GLP-1 users versus 3.8 among comparison groups.
People taking medicines such as Ozempic, Wegovy, Mounjaro or Zepbound should not stop treatment on their own. Sudden, painless vision changes in one eye need prompt medical attention.
The U.S. Food and Drug Administration issued a safety communication on November 9, 2026, requiring new warnings in the prescribing information for all GLP-1 receptor agonists because of a potential increased risk of non-arteritic anterior ischemic optic neuropathy, or NAION. NAION can cause sudden, painless vision loss in one eye; the FDA has not told patients to stop treatment routinely.
What did the FDA announce?
The FDA is requiring manufacturers of all GLP-1 receptor agonist medicines to add NAION information to the “Warnings and Precautions” section of their labels. These medicines mimic a natural gut hormone involved in blood-sugar control and appetite regulation. They are used for type 2 diabetes and weight management, with some products also approved for other conditions.
The agency’s list includes Ozempic, Wegovy and Rybelsus; Mounjaro and Zepbound; and medicines such as Trulicity, Victoza, Saxenda and Foundayo. Tirzepatide, the ingredient in Mounjaro and Zepbound, also acts on the GIP receptor.
The FDA describes the risk as potential, not proven for every patient or product. Reuters independently reported the label change and named Ozempic, Wegovy, Mounjaro and Zepbound among the medicines affected.
This is a labeling action, not a recall or a blanket instruction to stop treatment. The goal is to help patients and prescribers recognize the risk.
What did the FDA's review actually find?
The FDA pooled data from 126 randomized, controlled trials across several GLP-1 medicines. The trials included 134,253 participants and 288,879 person-years of exposure. The agency identified 15 probable NAION events: 10 among GLP-1 users and five among placebo recipients, with none among people receiving other non-GLP-1 glucose-lowering medicines.
The estimated rate was 6.4 cases per 100,000 person-years among GLP-1 users, compared with 3.8 per 100,000 in the comparison group. That is a small absolute difference. These are rates over accumulated follow-up, not a prediction of an individual patient's chance of developing NAION in the next year.
The FDA also reviewed a real-world study of adults with type 2 diabetes who started treatment between 2019 and 2024. NAION rates were 30 to 32 cases per 100,000 person-years among GLP-1 users, 31 among people taking SGLT-2 inhibitors and 26 among people taking DPP-4 inhibitors. The agency found no statistically significant increase compared with SGLT-2 inhibitors, but did find an increase compared with DPP-4 inhibitors (hazard ratio 1.43; 95% confidence interval 1.02–2.01).
The evidence is not a simple, settled answer. The randomized-trial analysis contained few probable events, and the FDA said some adverse-event reports were difficult to interpret because conditions such as diabetes and high blood pressure can also be associated with NAION. Its review of available animal data did not identify a mechanism explaining how GLP-1 medicines might increase the risk.
Why does the warning matter?
Analysis: GLP-1 medicines are used for different health needs, including diabetes and weight management. A warning that applies across the drug class is relevant to a large group of patients, not just people taking a medicine specifically for weight loss.
NAION involves reduced blood flow to the front of the optic nerve. It can cause sudden, painless vision loss in one eye and may lead to permanent damage. Symptoms can include blind spots, tunnel vision, distorted colors or a blurry, hazy area.
The FDA lists smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease among possible NAION risk factors. These factors do not mean a person taking a GLP-1 medicine will develop the condition; they are reasons to discuss personal health history and new symptoms with a clinician.
The distinction between a possible risk and a proven cause matters. The FDA's findings justify a stronger label warning, but do not establish that GLP-1 treatment will cause NAION in an individual patient or that every medicine in the class carries identical risk.
What should patients do now?
Do not stop or change a prescription on your own. Ask the clinician who prescribed it or a pharmacist how the warning applies to your treatment.
Act promptly if vision changes occur. Contact a health professional right away for sudden, painless vision loss in one eye, new blind spots, tunnel vision, color distortion or a blurry or hazy area.
Mention any previous NAION diagnosis. The FDA says patients who have experienced NAION should discuss with their health professional whether to continue or stop a GLP-1 medicine.
Review your health history. Tell your clinician about relevant conditions, including diabetes, high blood pressure, sleep apnea, anemia or kidney disease.
Big Zero recently examined a different medication decision in its coverage of cardiovascular events after stopping statins. That study does not answer the GLP-1 question, but it reinforces why prescription changes should be discussed with a health professional.
What is still unknown and what to watch next?
The FDA communication does not give an individual risk estimate by drug, dose, treatment duration or reason for use. It also does not establish that one GLP-1 product is safer than another for NAION.
The FDA gave no deadline for manufacturers to update every label. Patients and clinicians should watch for revised prescribing information and research that may clarify which patients face higher risk.
The central point is that the FDA sees enough evidence of a possible rare but serious risk to require a warning, while important questions about cause and individual risk remain open.
FAQ
Which GLP-1 medicines are included in the FDA warning?
The FDA says the label change applies to all GLP-1 receptor agonist medicines. Its list includes Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Victoza, Saxenda and Foundayo, among others.
Does the FDA say Ozempic or Wegovy causes blindness?
No. The FDA says there may be an increased risk of rare NAION events and is requiring a warning, but that does not prove a medicine caused an event in a particular patient. The agency's clinical-trial analysis found very few probable cases.
What are the warning signs of NAION?
Warning signs can include sudden, painless vision loss in one eye, blind spots, missing areas of vision, tunnel vision, distorted colors or a hazy central area. The FDA says patients should contact a health professional right away if these symptoms occur.
Should I stop taking my GLP-1 medicine?
Do not stop or change the dose without speaking to your prescriber. If you have had NAION, the FDA specifically advises discussing whether to continue treatment with your health professional.
Bottom line
The FDA's new warning is a reason to know the symptoms and review your treatment with a clinician, not to stop a GLP-1 medicine abruptly. If sudden or unusual vision changes affect one eye, seek medical advice right away.
